Jie Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jie Xiao has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Dan Xu
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 shared publications - Dongjun Lin
Department of Hematology, the Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China
11 shared publications - Guangyang Weng
Department of Hematology, Shenzhen Second People’s Hospital, Shenzhen, China
11 shared publications - Guopan Yu
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 shared publications - Hongyu Zhang
Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, People’s Republic of China
11 shared publications - Hua Jin
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 shared publications
Latest Publications
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S1. Analysis of pairwise co-mutation and mutual exclusivity in the top 20 most frequently detected gene mutations.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S1. Analysis of pairwise co-mutation and mutual exclusivity in the top 20 most frequently detected gene mutations.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S4. Subgroup analyses of the CRc rate of VAH versus VA based on genetic patterns.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S4. Subgroup analyses of the CRc rate of VAH versus VA based on genetic patterns.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S5. The 167-gene next generation sequencing panel.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S5. The 167-gene next generation sequencing panel.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S2. Treatment response rates by co-mutations.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S2. Treatment response rates by co-mutations.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S5. Incorporating HHT to overcome VEN resistance.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S5. Incorporating HHT to overcome VEN resistance.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S1. Genetic characteristics according to treatment group.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S1. Genetic characteristics according to treatment group.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S2. Univariable and Multivariable analyses for the survival of the whole corhot.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S2. Univariable and Multivariable analyses for the survival of the whole corhot.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S3. Treatment-emergent adverse events in the VA versus VAH group.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Table S3. Treatment-emergent adverse events in the VA versus VAH group.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S4. Survival outcomes in VA and VAH patients depending on FLT3-ITD mutation.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S4. Survival outcomes in VA and VAH patients depending on FLT3-ITD mutation.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S3. Prognostic effect of VA and VAH on OS in genetic subgroups.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Supplementary Figure S3. Prognostic effect of VA and VAH on OS in genetic subgroups.